Key Takeaways
- • Precision Neuroscience closed a $250 million oversubscribed Series D at approximately $1 billion valuation, led by Pershing Square Inc., the Ackman Oxman Institute, and an unnamed life sciences fund, with Pershing Square and Ackman Oxman contributing $42.5 million jointly.
- • The company has now raised approximately $430 million in cumulative capital, positioning it as a late-stage neurotech player attracting institutional capital from family offices, sovereign wealth vehicles, and venture/growth investors.
- • Series D proceeds will fund clinical advancement and commercialization of Precision Neuroscience's Layer 7 cortical interface, a brain-computer interface technology targeting the institutional neurotech investment thesis.
- • The round attracted a diversified LP base including Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, and JSL Health Capital, reflecting broad institutional conviction in the asset class.
- • For crossover and life-sciences allocators, the $1 billion-plus valuation and oversubscription signal maturing commercial pathways in cortical interface technology and sustained institutional demand for late-stage neurotech exposure.
Summary
Precision Neuroscience announced on September 24, 2026 a $250 million Series D funding round that was oversubscribed, according to company filings via GlobeNewswire. The round achieved a valuation of approximately $1 billion, as reported by The New York Times and cited by The Next Web. The financing was co-led by Pershing Square Inc., the Ackman Oxman Institute, and an unnamed life sciences investment fund, with Pershing Square and the Ackman Oxman Institute jointly committing $42.5 million to the round.
The Series D attracted participation from a broad institutional investor base reflecting conviction across multiple allocation strategies. Named investors include Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, and JSL Health Capital. The diversity of investor types—spanning family offices, growth-stage venture capital, sovereign wealth vehicles, and specialized neurotech-focused managers—underscores institutional appetite for late-stage brain-computer interface opportunities.
With the Series D close, Precision Neuroscience has raised approximately $430 million in total capital to date. The company designated Series D proceeds for advancement of clinical programs and commercialization of its Layer 7 cortical interface technology. For institutional allocators tracking the neurotech sector, the $250 million round size, $1 billion valuation, and oversubscription status highlight accelerating commercialization timelines and sustained investor demand for cortical interface platforms positioned for clinical deployment and market adoption.
The Series D attracted participation from a broad institutional investor base reflecting conviction across multiple allocation strategies. Named investors include Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, and JSL Health Capital. The diversity of investor types—spanning family offices, growth-stage venture capital, sovereign wealth vehicles, and specialized neurotech-focused managers—underscores institutional appetite for late-stage brain-computer interface opportunities.
With the Series D close, Precision Neuroscience has raised approximately $430 million in total capital to date. The company designated Series D proceeds for advancement of clinical programs and commercialization of its Layer 7 cortical interface technology. For institutional allocators tracking the neurotech sector, the $250 million round size, $1 billion valuation, and oversubscription status highlight accelerating commercialization timelines and sustained investor demand for cortical interface platforms positioned for clinical deployment and market adoption.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.